Form 1 Millery Survey

Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery (NCI)

0925-0642-03 Millery Survey

Translational Advances in Cancer Prevention Agent Development Meeting Survey (NCI)

OMB: 0925-0642

Document [pdf]
Download: pdf | pdf
Thank you for completing the Translational Advances in Cancer Prevention Agent Development
Meeting Survey program!
OMB No. 0925-0642
Expiration Date: 03/31/2023
Public reporting burden for this collection of information is estimated to average 15 minutes per
response, including the time for reviewing instructions, searching existing data sources,
gathering and maintaining the data needed, and completing and reviewing the collection of
information. An agency may not conduct or sponsor, and a person is not required to respond to,
a collection of information unless it displays a currently valid OMB control number. Send
comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705
Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0642). Do not return
the completed form to this address.
Please reflect on your experience in the Translational Advances in Cancer Prevention Agent
Development Program.
This survey should take approximately 15 minutes to complete.

Translational Advances in Cancer Prevention Agent
Development
August 27-29, 2020
MEETING SURVEY
Excellent
How did the meeting meet your expectations?
(Check one box)

Comments:

Very
Good

Good

Fair

Poor

Please rank the following meeting
elements:
Excellent

Very
Good

Good

Website
Registration Process
Poster Session
Demonstrations
Venue
Hotel
Scientific Sessions:
Plenary Sessions
Advances in Small Molecule Agent
Development
Advances in Immunomodulatory Agent
Development
Alternative Dosing and Combination
Strategies to Reduce Toxicity
Emerging
Vaccines
for
Cancer
Prevention
Cancer Prevention Clinical Trials
Comments:
What topics would you like to have addressed in next year’s program?

Comments / Thoughts? (continue on back page if needed)

Fair

Poor

NCI Information Sessions:
NCI PREVENT Preclinical Drug Development
Program
Overview of the Cancer Prevention Clinical
Trials Network (CP-CTNet)
Comments / Thoughts?

If this meeting was scheduled to occur on a regular basis once every 2 years, how likely is
it that you would plan on attending regularly?
_____ Definitely
_____ Likely
_____ Unlikely

Comments / Thoughts?


File Typeapplication/pdf
AuthorMorales, Sussana (NIH/NCI) [E]
File Modified2020-04-01
File Created2020-04-01

© 2024 OMB.report | Privacy Policy